Monotherapy: Key cause of macrolide-resistant Mycobacterium avium complex disease.

Daniel Loewenstein, Lars van Balveren, Arthur Lemson, Nicolien Hanemaaijer, Wouter Hoefsloot, Jakko van Ingen
Author Information
  1. Daniel Loewenstein: Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
  2. Lars van Balveren: Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
  3. Arthur Lemson: Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  4. Nicolien Hanemaaijer: Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
  5. Wouter Hoefsloot: Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  6. Jakko van Ingen: Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: jakko.vaningen@radboudumc.nl.

Abstract

BACKGROUND: Macrolide-resistant Mycobacterium avium complex (MAC) disease is very difficult to cure. Macrolide-resistance emerges in patients and is largely preventable by appropriate screening and treatment practices.
METHODS: Patients with macrolide-resistant MAC isolates between March 2019 and March 2022 were retrieved from the mycobacteriology reference laboratory database at Radboudumc, Nijmegen, the Netherlands. Clinical consultation reports were extracted from the database to assess the cause of macrolide resistance.
RESULTS: Sixteen patients with macrolide-resistant MAC disease were included, from a total of 815 patients with MAC isolates (2%); Macrolide monotherapy in bronchiectasis or CF was the most frequent cause of development of macrolide-resistance MAC disease (n = 8; 50%). Short (n = 3; mean duration 9 months, range 6-12) or guideline non-compliant (n = 2) treatment regimens and patient non-adherence (n = 2) were other key causes of macrolide-resistance.
CONCLUSIONS: Macrolide monotherapy after inappropriate screening is the most frequent cause of macrolide-resistant Mycobacterium avium complex disease in the Netherlands. Educational efforts are needed to prevent this.

MeSH Term

Humans
Mycobacterium avium Complex
Anti-Bacterial Agents
Macrolides
Mycobacterium avium-intracellulare Infection
Drug Resistance, Bacterial
Lung Diseases

Chemicals

Anti-Bacterial Agents
Macrolides

Word Cloud

Created with Highcharts 10.0.0MACdiseasemacrolide-resistantcauseMycobacteriumaviumcomplexpatientsscreeningtreatmentisolatesMarchdatabaseNetherlandsMacrolidemonotherapyfrequentmacrolide-resistancen = 2BACKGROUND:Macrolide-resistantdifficultcureMacrolide-resistanceemergeslargelypreventableappropriatepracticesMETHODS:Patients20192022retrievedmycobacteriologyreferencelaboratoryRadboudumcNijmegenClinicalconsultationreportsextractedassessmacrolideresistanceRESULTS:Sixteenincludedtotal8152%bronchiectasisCFdevelopmentn = 850%Shortn = 3meanduration9monthsrange6-12guidelinenon-compliantregimenspatientnon-adherencekeycausesCONCLUSIONS:inappropriateEducationaleffortsneededpreventthisMonotherapy:Key

Similar Articles

Cited By